Old Web
English
Sign In
Acemap
>
authorDetail
>
Sheldon I. Bastacky
Sheldon I. Bastacky
University of Pittsburgh
Medicine
Rituximab
Obinutuzumab
Antibody
Monoclonal antibody
4
Papers
6
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The hepatocyte growth factor/c-met pathway is a key determinant of the fibrotic kidney local microenvironment.
2021
iScience
Haiyan Fu
Yuan Gui
Silvia Liu
Yuanyuan Wang
Sheldon I. Bastacky
Yi Qiao
Rong Zhang
Christopher P. Bonin
Geneva Hargis
Yanbao Yu
Donald L. Kreutzer
Partha S. Biswas
Yanjiao Zhou
Yanlin Wang
Xiao-Jun Tian
Youhua Liu
Dong Zhou
Show All
Source
Cite
Save
Citations (0)
Absolute quantitative proteomics using the total protein approach to identify novel clinical immunohistochemical markers in renal neoplasms.
2021
BMC Medicine
Susana Jorge
José Luis Capelo
William A. LaFramboise
Swati Satturwar
Dimitrios Korentzelos
Sheldon I. Bastacky
Gabriela Quiroga-Garza
Rajiv Dhir
Jacek R. Wiśniewski
Carlos Lodeiro
Hugo M. Santos
Show All
Source
Cite
Save
Citations (1)
Bladder infection with uropathogenic Escherichia coli increases the excitability of afferent neurons.
2021
American Journal of Physiology-renal Physiology
Nicolas Montalbetti
Marianela G. Dalghi
Sheldon I. Bastacky
Dennis R. Clayton
Wily G. Ruiz
Gerard Apodaca
Marcelo D. Carattino
Show All
Source
Cite
Save
Citations (0)
The Type II anti-CD20 Antibody Obinutuzumab (GA101) is More Effective than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
2020
Arthritis & Rheumatism
Anthony D. Marinov
Haowei Wang
Sheldon I. Bastacky
Erwin van Puijenbroek
Thomas Schindler
Dario Speziale
Mario Perro
Christian Klein
Kevin M. Nickerson
Mark J. Shlomchik
Show All
Source
Cite
Save
Citations (5)
1